Sector News

Merck KGaA appoints Allan Gabor as managing director in China

December 12, 2017
Life sciences

Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.

The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.

Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.

Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.

Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.

By Marc Navarro Gonzalez

Source: Dow Jones Newswires via Fox Business

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.